Digital analytics provider Health Catalyst Inc and digital therapeutics company MedRhythms Inc are teaming up to help stroke survivors to access a new digital therapeutic engineered to use sensors, music, and artificial intelligence to measure and improve walking.
The neuroscience-based approach to treatment developed by MedRhythms employs the principles of rhythmic auditory stimulation (RAS), which researchers suggest may help improve walking for patients with stroke, traumatic brain injury, multiple sclerosis, cerebral palsy, and Parkinson’s disease.
Via their partnership, the companies will deploy new methods for pinpointing patients who could benefit from MedRhythms’ therapeutics, accurately measuring their clinical outcomes and enabling MedRhythm’s integration within the provider clinical workflow, according to a media release from MedRhythms Inc.
“Health Catalyst will leverage our services and relationships with some of the nation’s largest provider organizations to develop a convenient means of providing MedRhythms’ products and those of life science companies in general within the clinical workflow, in a manner that’s respectful of clinicians’ existing care processes,” says Elia Stupka, PhD, general manager of Health Catalyst’s life science business, in the release.
Under the agreement, Health Catalyst will use real-world data and analytic applications to identify unmet medical needs within the care of neurologic injury and disease. The methodology leverages Health Catalyst’s analytics to uncover variation in outcome metrics and care within healthcare organizations.
As best practices for patient care are identified through this process and put into practice by provider organizations, patients are identified as potential beneficiaries of a new medication or digital therapy such as MedRhythms product. By standardizing the way in which both clinical outcomes and cost reductions are measured, a reliable framework can be developed to measure effectiveness and structure outcome-based pricing that can be applied to the digital therapy, the release continues.
“This partnership with Health Catalyst is a true milestone in our effort to develop digital therapeutics based on the neuroscience of music,” states Owen McCarthy, president and co-founder of MedRhythms.
“This partnership comes at a crucial time in the digital therapeutics industry,” adds Carlos Rodarte, senior vice president of strategy and business development for the life sciences at Health Catalyst, and renowned thought leader in digital health. “We are excited to leverage our technological platform, outcome expertise and trusted network of providers to support digital therapeutics companies like MedRhythms.”
“We believe it’s time for a trusted company with proven expertise to take a different run at building partnerships between providers and life science companies, as a neutral party focused on improved health and wellness for patients,” Stupka concludes, in the release.
“This agreement with MedRhythms aligns perfectly with our mission of serving as a catalyst for massive, sustained improvements in healthcare outcomes.”
[Source(s): MedRhythms Inc, PR Newswire]